John Reese

|RSS

John P. Reese is founder and CEO of Validea.com, an investment research firm, and Validea Capital Management, an asset management firm serving affluent investors and companies. He is also co-author of two investing books, including The Guru Investor: How to Beat the Market Using History's Best Investment Strategies (Wiley).Expand

Before Validea, Reese was vice president of information technology for GE Capital ITS, president and CEO of Micro Networks of America, a networking firm, and marketing manager of electronics at Coleco.

Reese holds a master's of business administration from Harvard Business School and a bachelor's degree in computer science from the Massachusetts Institute of Technology.Collapse

By

John Reese

 | Apr 13, 2012 | 7:58 AM EDT

Mid-cap stocks have historically outperformed all the rest, and these three are particularly solid choices.

By

John Reese

 | Apr 10, 2012 | 11:30 AM EDT

This stock screen takes a thorough look at the bottom line -- and these three names make the cut.

By

John Reese

 | Apr 4, 2012 | 6:30 AM EDT

The Chinese economy could be in for what some see as a pre-election surge.

By

John Reese

 | Mar 28, 2012 | 9:30 AM EDT

The company is cooking, and it looks like a good time to add the stock to your portfolio’s menu.

By

John Reese

 | Mar 26, 2012 | 3:00 PM EDT

I have identified three stocks that are worth buying today that fit this criteria as well as certain guru strategies.

By

John Reese

 | Mar 23, 2012 | 2:45 PM EDT
Eating is taking precedent over running, at least according to my guru analysis. Nike (NKE) and Darden Restaurants (DRE), operator of Olive Garden...
By

John Reese

 | Mar 22, 2012 | 9:30 AM EDT

These tech growth names all pay a dividend, and they've garnered approval from my demanding stock screens.

By

John Reese

 | Mar 20, 2012 | 7:25 AM EDT

Russia's oil stocks -- and this one, in particular -- are looking to have a very good 2012.

By

John Reese

 | Mar 19, 2012 | 10:30 AM EDT

As evidence mounts that retail is on the mend, these three stocks particularly stand out.

By

John Reese

 | Mar 13, 2012 | 7:30 AM EDT

Biotech and pharma companies have the biggest edge in pricing power.

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.